Clinical Updates in Polydeoxyribonucleotide Injection
10.4055/jkoa.2024.59.6.386
- Author:
Tae-Yeong KIM
1
;
Yong-Tae KIM
;
Jung-Taek HWANG
Author Information
1. Department of Orthopaedic Surgery, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Korea
- Publication Type:Symposium
- From:The Journal of the Korean Orthopaedic Association
2024;59(6):386-394
- CountryRepublic of Korea
- Language:English
-
Abstract:
Polydeoxyribonucleotide (PDRN) is a DNA-derived drug with a molecular weight of 50 to 1,500 kDa that is extracted from the sperm of fish such as salmon, trout, and sturgeon. PDRN activates the adenosine A2 receptor and salvage pathway, promoting bone cell activity, collagen synthesis, and angiogenesis. Numerous preclinical and clinical studies have described the wound healing and anti-inflammatory effects of PDRN. PDRN enhances tendon-to-bone healing in rotator cuff injuries, reduces fat degeneration, and has positive clinical effects on pain relief and functional recovery. In vivo studies on Achilles tendon injuries have shown that PDRN promotes collagen synthesis, inhibits cell apoptosis, and reduces inflammatory responses. In lateral epicondylitis of the elbow, PDRN administration improves pain and increases the thickness of tendons. PDRN has been reported to alleviate pain in plantar fasciitis. Moreover, PDRN promotes re-epithelialization in wound healing, diabetic ulcers, and pressure ulcers, leading to shortened healing periods and positive outcomes. In degenerative arthritis, PDRN administration has comparable or even superior effects to hyaluronic acid treatment. Numerous preclinical and clinical studies show that PDRN is a promising therapeutic approach for musculoskeletal disorders and skin healing, serving as an effective tissue regeneration stimulant.
